← All trials
NCT02057757
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2014
- Primary completion
- May 1, 2017
- Completion date
- Jun 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 290
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOverall official - principal investigator
- Government of MexicoOverall official - principal investigator
- Universidad Autonoma de San Luis PotosiOverall official - principal investigator
- Instituto Nacional De PediatriaOverall official - principal investigator
- Instituto Nacional De Enfermedades Respiratorias Ismael Cosio VillegasOverall official - principal investigator
- Hospital General Dr. Aurelio ValdiviesoOverall official - principal investigator
- Mexican Emerging Infectious Diseases Clinical Research NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.